Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 May 2008, Vol. 111, No. 9, pp. 4681-4689.
Prepublished online as a Blood First Edition Paper on January 28, 2008; DOI 10.1182/blood-2007-11-125278.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2007-11-125278v1
111/9/4681    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hewamana, S.
Right arrow Articles by Pepper, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hewamana, S.
Right arrow Articles by Pepper, C.
Related Collections
Right arrow Neoplasia
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

The NF-{kappa}B subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target

Saman Hewamana1,2, Suhair Alghazal1, Thet Thet Lin1, Matthew Clement2, Chris Jenkins1, Monica L. Guzman3, Craig T. Jordan3, Sundar Neelakantan4, Peter A. Crooks4, Alan K. Burnett1, Guy Pratt5, Chris Fegan1, Clare Rowntree1, Paul Brennan2, and Chris Pepper1

Departments of1 Haematology and 2 Medical Biochemistry & Immunology, School of Medicine, Cardiff University, Cardiff, United Kingdom; 3 Division of Hematology/Oncology, University of Rochester School of Medicine, Rochester, NY; 4 Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington; and 5 Department of Haematology, Birmingham Heartlands Hospital, Birmingham, United Kingdom

In this study, we characterized nuclear factor {kappa}B (NF-{kappa}B) subunit DNA binding in chronic lymphocytic leukemia (CLL) samples and demonstrated heterogeneity in basal and inducible NF-{kappa}B. However, all cases showed higher basal NF-{kappa}B than normal B cells. Subunit analysis revealed DNA binding of p50, Rel A, and c-Rel in primary CLL cells, and Rel A DNA binding was associated with in vitro survival (P = .01) with high white cell count (P = .01) and shorter lymphocyte doubling time (P = .01). NF-{kappa}B induction after in vitro stimulation with anti-IgM was associated with increased in vitro survival (P < .001) and expression of the signaling molecule ZAP-70 (P = .003). Prompted by these data, we evaluated the novel parthenolide analog, LC-1, in 54 CLL patient samples. LC-1 induced apoptosis in all the samples tested with a mean LD50 of 2.8 µM after 24 hours; normal B and T cells were significantly more resistant to its apoptotic effects (P < .001). Apoptosis was preceded by a marked loss of NF-{kappa}B DNA binding and sensitivity to LC-1 correlated with basal Rel A DNA binding (P = .03, r2 = 0.15). Furthermore, Rel A DNA binding was inversely correlated with sensitivity to fludarabine (P = .001, r2 = 0.3), implicating Rel A in fludarabine resistance. Taken together, these data indicate that Rel A represents an excellent therapeutic target for this incurable disease.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

CLL and activated NF-{kappa}B: living partnership
Erin Hertlein and John C. Byrd
Blood 2008 111: 4427. [Full Text] [PDF]



This article has been cited by other articles:


Home page
BloodHome page
T. Enzler, A. P. Kater, W. Zhang, G. F. Widhopf II, H.-Y. Chuang, J. Lee, E. Avery, C. M. Croce, M. Karin, and T. J. Kipps
Chronic lymphocytic leukemia of E{micro}-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression
Blood, November 12, 2009; 114(20): 4469 - 4476.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S.-S. Chen, A. Raval, A. J. Johnson, E. Hertlein, T.-H. Liu, V. X. Jin, M. H. Sherman, S.-J. Liu, D. W. Dawson, K. E. Williams, et al.
Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia
PNAS, August 11, 2009; 106(32): 13433 - 13438.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Lopez-Guerra, G. Roue, P. Perez-Galan, R. Alonso, N. Villamor, E. Montserrat, E. Campo, and D. Colomer
p65 Activity and ZAP-70 Status Predict the Sensitivity of Chronic Lymphocytic Leukemia Cells to the Selective I{kappa}B Kinase Inhibitor BMS-345541
Clin. Cancer Res., April 15, 2009; 15(8): 2767 - 2776.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Hewamana, T. T. Lin, C. Rowntree, K. Karunanithi, G. Pratt, R. Hills, C. Fegan, P. Brennan, and C. Pepper
Rel A Is an Independent Biomarker of Clinical Outcome in Chronic Lymphocytic Leukemia
J. Clin. Oncol., February 10, 2009; 27(5): 763 - 769.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Hewamana, T. T. Lin, C. Jenkins, A. K. Burnett, C. T. Jordan, C. Fegan, P. Brennan, C. Rowntree, and C. Pepper
The Novel Nuclear Factor-{kappa}B Inhibitor LC-1 Is Equipotent in Poor Prognostic Subsets of Chronic Lymphocytic Leukemia and Shows Strong Synergy with Fludarabine
Clin. Cancer Res., December 15, 2008; 14(24): 8102 - 8111.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020